within Pharmacolibrary.Drugs.ATC.G;

model G04CA02
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.7,
    Cl             = 0.00011,
    adminDuration  = 600,
    adminMass      = 0.4 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.016,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0050999999999999995,
    Tlag           = 15.0,            
    Vdp             = 0.038,
    k12             = 5.5,
    k21             = 5.5
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>G04CA02</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Tamsulosin is an alpha-1 adrenergic receptor antagonist primarily used to treat the symptoms of benign prostatic hyperplasia (BPH) in men. It helps relax the muscles in the prostate and bladder neck, making it easier to urinate. Tamsulosin is approved and widely used today for this indication.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in healthy adult male volunteers receiving single oral dose of tamsulosin fasting.</p><h4>References</h4><ol><li><p>Franco-Salinas, G, et al., &amp; Michel, MC (2010). Pharmacokinetics and pharmacodynamics of tamsulosin in its modified-release and oral controlled absorption system formulations. <i>Clinical pharmacokinetics</i> 49(3) 177–188. DOI:<a href=\"https://doi.org/10.2165/11317580-000000000-00000\">10.2165/11317580-000000000-00000</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/20170206/\">https://pubmed.ncbi.nlm.nih.gov/20170206</a></p></li><li><p>Li, H, et al., &amp; Wang, C (2015). Effect of tamsulosin on the pharmacokinetics of dutasteride in Chinese male healthy volunteers. <i>Clinical pharmacology in drug development</i> 4(6) 427–433. DOI:<a href=\"https://doi.org/10.1002/cpdd.197\">10.1002/cpdd.197</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/27137714/\">https://pubmed.ncbi.nlm.nih.gov/27137714</a></p></li><li><p>Schulman, CC (2008). Tamsulosin modified release and oral controlled absorption system in the management of lower urinary tract symptoms suggestive of benign prostatic hyperplasia. <i>Expert opinion on drug metabolism &amp; toxicology</i> 4(6) 771–782. DOI:<a href=\"https://doi.org/10.1517/17425255.4.6.771\">10.1517/17425255.4.6.771</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/18611117/\">https://pubmed.ncbi.nlm.nih.gov/18611117</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end G04CA02;
